DE69822626T8 - Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs - Google Patents

Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs Download PDF

Info

Publication number
DE69822626T8
DE69822626T8 DE69822626T DE69822626T DE69822626T8 DE 69822626 T8 DE69822626 T8 DE 69822626T8 DE 69822626 T DE69822626 T DE 69822626T DE 69822626 T DE69822626 T DE 69822626T DE 69822626 T8 DE69822626 T8 DE 69822626T8
Authority
DE
Germany
Prior art keywords
cancer
nitroxide
prodrug
prophylactic
therapeutic treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE69822626T
Other languages
German (de)
English (en)
Other versions
DE69822626D1 (de
DE69822626T2 (de
Inventor
B. James MITCHELL
Angelo Russo
Marie Anne DELUCA
Krishna Murali CHERUKURI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of DE69822626D1 publication Critical patent/DE69822626D1/de
Application granted granted Critical
Publication of DE69822626T2 publication Critical patent/DE69822626T2/de
Publication of DE69822626T8 publication Critical patent/DE69822626T8/de
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DE69822626T 1997-05-27 1998-05-27 Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs Active DE69822626T8 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4772497P 1997-05-27 1997-05-27
US47724P 1997-05-27
PCT/US1998/010685 WO1998053835A1 (en) 1997-05-27 1998-05-27 The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer

Publications (3)

Publication Number Publication Date
DE69822626D1 DE69822626D1 (de) 2004-04-29
DE69822626T2 DE69822626T2 (de) 2004-08-12
DE69822626T8 true DE69822626T8 (de) 2005-02-03

Family

ID=21950574

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69822626T Active DE69822626T8 (de) 1997-05-27 1998-05-27 Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs

Country Status (10)

Country Link
EP (1) EP0986393B1 (https=)
JP (3) JP4856294B2 (https=)
AT (1) ATE262330T1 (https=)
AU (1) AU746505B2 (https=)
CA (1) CA2289017C (https=)
DE (1) DE69822626T8 (https=)
DK (1) DK0986393T3 (https=)
ES (1) ES2216286T3 (https=)
PT (1) PT986393E (https=)
WO (1) WO1998053835A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096759A (en) * 1997-09-19 2000-08-01 Georgetown University Method for treating essential hypertension
AU765110B2 (en) * 1998-06-26 2003-09-11 Georgetown University Medical Center Compositions and methods for inducing cell death
US20040219201A1 (en) * 2001-12-06 2004-11-04 Yechezkel Barenholz Tempamine compositions and methods of use
JP2007500227A (ja) * 2003-05-29 2007-01-11 ミトス・ファーマシューティカルズ・インコーポレーテッド 光増感剤及び音増感剤と関連してのニトロキシドの使用方法
WO2006084197A2 (en) * 2005-02-02 2006-08-10 Mitos Pharmaceuticals, Inc. Nitroxides for use in treating or preventing neoplastic disease
US8466130B2 (en) 2009-09-04 2013-06-18 Colby Pharmaceutical Company Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers
WO2008109740A2 (en) * 2007-03-06 2008-09-12 Colby Pharmaceutical Company Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers
US8853277B2 (en) 2009-11-30 2014-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC)
US10231959B2 (en) 2016-03-23 2019-03-19 Louis Habash Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
JP2019509352A (ja) * 2016-03-23 2019-04-04 ルイス ハバシュ, ヒトの被験物質をニトロキシドで処理することによってapoptosis関連遺伝子の発現レベルを増加させる
US20180078539A1 (en) 2016-03-23 2018-03-22 Louis Habash T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758580A (en) * 1985-06-26 1988-07-19 Yamanouchi Pharmaceutical Co., Ltd. Inhibiting growth of tumors with certain substituted phenoxy dimethyl alkanoic acids, esters or salts
DK0462305T3 (da) * 1990-06-21 1995-04-24 Huland Edith Anvendelse af cytokinholdige aerosoler såvel som cytokholdige aerosoler i sig selv
US6605619B1 (en) * 1992-03-20 2003-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxides as protectors against oxidatives stress
AU4788396A (en) * 1995-02-16 1996-09-04 Children's Medical Center Corporation Inhibition of angiogenesis using interleukin-12

Also Published As

Publication number Publication date
AU7598798A (en) 1998-12-30
DE69822626D1 (de) 2004-04-29
JP5270413B2 (ja) 2013-08-21
ES2216286T3 (es) 2004-10-16
AU746505B2 (en) 2002-05-02
JP2009185034A (ja) 2009-08-20
JP2002500671A (ja) 2002-01-08
EP0986393A1 (en) 2000-03-22
JP4856294B2 (ja) 2012-01-18
JP2013121964A (ja) 2013-06-20
EP0986393B1 (en) 2004-03-24
DE69822626T2 (de) 2004-08-12
CA2289017C (en) 2008-07-22
DK0986393T3 (da) 2004-07-05
WO1998053835A1 (en) 1998-12-03
CA2289017A1 (en) 1998-12-03
ATE262330T1 (de) 2004-04-15
PT986393E (pt) 2004-06-30

Similar Documents

Publication Publication Date Title
DE69634776D1 (de) Verwendung eines r-nsaid als chemoschützendes mittel zur behandlung kolorektales krebs
DE69433889D1 (de) Anwendung von 1,2,4-benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren
ATE399547T1 (de) Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und vorbeugung von neoplasia
ATE499934T1 (de) Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs
ATE198044T1 (de) Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DE60124085D1 (de) Pde-v hemmer zur behandlung von morbus parkinson
ATE362363T1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
ATE242632T1 (de) Verwendung von betulinsäure-derivaten zur behandlung und vorbeugung von melanomen
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
DE69822626T8 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
ATE260282T1 (de) Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
DE69707372D1 (de) Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE60130030D1 (de) Verfahren zur behandlung von glaukom
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
DE50109320D1 (de) Verwendung von 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS

8364 No opposition during term of opposition